Despite not having FDA approval, Ozempic gained popularity for weight loss, causing drug shortages in the US and social media crackdowns on off-label promotion.
Novo Nordisk denies promoting off-label use but observers notice a shift in marketing strategy, focusing on Ozempic's weight loss appeal and direct-to-consumer approach.
[
add
]
[
|
|
...
]